Research Article

Preoperative and Postoperative Bone Mineral Density Change and Risk Factor Analysis in Patients with a GH-Secreting Pituitary Adenoma

Table 4

Correlation analysis of clinical data and the BMD Z score.

L1L2L3L4L1–L4L2–L4Femoral neckWard triangleTrochanterTotal hip

Age (years)r−0.110−0.125−0.156−0.125−0.123−0.131−0.0170.0680.056−0.039
0.5060.4490.3430.4470.4560.4250.9190.6820.7350.816
BMI (kg/m2)r−0.049−0.0480.069−0.034−0.014−0.0230.082−0.1020.0540.235
0.7680.7720.6750.8350.9310.8870.6180.5350.7420.150
Disease duration (months)R−0.389−0.370−0.371−0.371−0.413−0.393−0.280−0.276−0.319−0.324
0.0140.0210.0200.0200.0090.0130.0840.0880.0480.044
Adenoma size (mm)r0.0700.1830.1440.1470.1390.1550.1020.1200.1040.114
0.6700.2640.3830.3710.4000.3460.5350.4660.5280.488
GH (ng/mL)r0.2400.2720.1860.1780.2290.2140.1940.1010.1910.192
0.1400.0940.2570.2770.1610.1900.2360.5410.2450.241
IGF-1 (ng/mL)r0.0210.0970.0970.0960.0860.1060.1910.0410.1330.193
0.8970.5560.5590.5630.6030.5220.2440.8020.4210.240
IGF-1 burden (ng/mL  month)r−0.326−0.273−0.277−0.267−0.319−0.298−0.150−0.197−0.213−0.174
0.0420.0930.0880.1000.0480.0660.3620.2300.1940.291
FT3 (pg/mL)r−0.006−0.077−0.066−0.057−0.072−0.073−0.215−0.231−0.128−0.117
0.9700.6430.6920.7290.6650.6590.1880.1570.4360.477
FT4 (pg/mL)r−0.195−0.176−0.081−0.096−0.124−0.118−0.100−0.057−0.095−0.107
0.2340.2830.6230.5590.4520.4740.5430.7280.5640.518
PRL (ng/mL)r−0.129−0.184−0.219−0.240−0.227−0.234−0.329−0.255−0.361−0.313
0.4350.2630.1800.1420.1640.1510.0410.1170.0240.053
Ca (mmol/L)r0.1400.0570.0380.0010.0830.0540.2300.2500.2330.136
0.3960.7300.8190.9950.6140.7460.1590.1240.1540.411
P (mmol/L)r0.0770.0480.040−0.0390.0240.015−0.015−0.022−0.0250.042
0.6410.7710.8080.8120.8830.9290.9290.8970.8780.801

BMI: body mass index; GH: growth hormone; IGF-1: insulin-like growth factor-1; FT3: free triiodothyronine; FT4: free thyroxine; PRL: prolactin; Ca: calcium; P: phosphorus.